Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
AND had received a first course of chemotherapy for diffuse large B cell lymphoma or for follicular lymphoma
Life expectancy \> 6 months.
Negative pregnancy test.
Having signed the consent form.
Having an health insurance.
You may not be if
Receiving monoclonal antibodies or biotherapies altering the immune response, other than anti-CD20 antibodies in the chemotherapy protocol.
Uncontrolled bacterial, viral or fungal infection less than 7 days.
Previous vaccination with PCV13 or PPV23 (unless PCV13 was administered in childhood. The last injection must be performed at least five years ago).
Preexisting condition that altered the immune response: splenectomy, HIV, primary or secondary immune deficiency, nephrotic syndrome, sickle cell anemia, autoimmune disorder, solid organ transplantation, immunosuppressive drugs or biotherapy not included in the chemotherapy.
Patient who already received chemotherapy for malignancy in the previous 2 years before the inclusion.
Major blood clotting disorders preventing intramuscular injection.
Medical history of anaphylactic reaction to vaccination.
Known allergy to one of the vaccine components.
Involvement to another vaccine biomedical research.
Protected person.
Pregnant women or women of childbearing age without appropriate contraceptive measures.
Perfusion of polyvalent immunoglobulins during follow-up.
Participants with hypersensitivity to aluminum phosphate, phenol or CRM197 protein, protein derived from Corynebacterium diphtheria.